161 related articles for article (PubMed ID: 26687384)
1. The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom.
Schmidt N; Jacob L; Coleman R; Kostev K; Hadji P
Breast Cancer Res Treat; 2016 Jan; 155(1):151-7. PubMed ID: 26687384
[TBL] [Abstract][Full Text] [Related]
2. Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany.
Jacob L; Hadji P; Kostev K
J Geriatr Oncol; 2016 May; 7(3):169-75. PubMed ID: 27091510
[TBL] [Abstract][Full Text] [Related]
3. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis.
Hadji P; Ziller V; Kyvernitakis J; Bauer M; Haas G; Schmidt N; Kostev K
Breast Cancer Res Treat; 2013 Feb; 138(1):185-91. PubMed ID: 23334803
[TBL] [Abstract][Full Text] [Related]
4. Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy.
Neuner JM; Shi Y; Kong AL; Kamaraju S; Smith EC; Smallwood AJ; Laud PW; Charlson JA
J Cancer Surviv; 2018 Apr; 12(2):268-275. PubMed ID: 29243101
[TBL] [Abstract][Full Text] [Related]
5. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
[TBL] [Abstract][Full Text] [Related]
6. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Mincey BA; Duh MS; Thomas SK; Moyneur E; Marynchencko M; Boyce SP; Mallett D; Perez EA
Clin Breast Cancer; 2006 Jun; 7(2):127-32. PubMed ID: 16800971
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.
Eggemann H; Altmann U; Costa SD; Ignatov A
J Cancer Res Clin Oncol; 2018 Feb; 144(2):337-341. PubMed ID: 29098396
[TBL] [Abstract][Full Text] [Related]
8. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.
Ligibel JA; James O'Malley A; Fisher M; Daniel GW; Winer EP; Keating NL
Breast Cancer Res Treat; 2012 Jan; 131(2):589-97. PubMed ID: 21881937
[TBL] [Abstract][Full Text] [Related]
9. Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study.
Pineda-Moncusí M; Servitja S; Tusquets I; Diez-Perez A; Rial A; Cos ML; Campodarve I; Rodriguez-Morera J; Garcia-Giralt N; Nogués X
Breast Cancer Res Treat; 2019 Aug; 177(1):53-60. PubMed ID: 31127467
[TBL] [Abstract][Full Text] [Related]
10. Bone health history in breast cancer patients on aromatase inhibitors.
Kwan ML; Lo JC; Tang L; Laurent CA; Roh JM; Chandra M; Hahn TE; Hong CC; Sucheston-Campbell L; Hershman DL; Quesenberry CP; Ambrosone CB; Kushi LH; Yao S
PLoS One; 2014; 9(10):e111477. PubMed ID: 25354083
[TBL] [Abstract][Full Text] [Related]
11. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
12. Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
Yao S; Laurent CA; Roh JM; Lo J; Tang L; Hahn T; Ambrosone CB; Kushi LH; Kwan ML
Breast Cancer Res Treat; 2020 Feb; 180(1):187-195. PubMed ID: 31912328
[TBL] [Abstract][Full Text] [Related]
13. Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan.
Taguchi T; Matsushima H; Kodama S; Okubo N; Ito T; Ludwikowska M; Fukumoto S; Matsumoto T
Expert Opin Pharmacother; 2024 Feb; 25(3):325-334. PubMed ID: 38588537
[TBL] [Abstract][Full Text] [Related]
14. Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer.
Koopal C; Janssen-Heijnen ML; van de Wouw AJ; van den Bergh JP
Breast; 2015 Apr; 24(2):153-8. PubMed ID: 25618224
[TBL] [Abstract][Full Text] [Related]
15. Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
Oncologist; 2019 Nov; 24(11):1432-1438. PubMed ID: 31292269
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
Kwan ML; Lo JC; Laurent CA; Roh JM; Tang L; Ambrosone CB; Kushi LH; Quesenberry CP; Yao S
J Cancer Surviv; 2023 Feb; 17(1):139-149. PubMed ID: 33565036
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer.
Becker T; Lipscombe L; Narod S; Simmons C; Anderson GM; Rochon PA
J Am Geriatr Soc; 2012 Sep; 60(9):1761-7. PubMed ID: 22985145
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.
Erman A; Nugent A; Amir E; Coyte PC
Breast Cancer Res Treat; 2014 Jun; 145(2):267-79. PubMed ID: 24771048
[TBL] [Abstract][Full Text] [Related]
19. Bayesian synthesis using prior information on fracture risk from randomized trials to analyze post-market data.
John-Baptiste A; Becker T; Fung K; Lipscombe LL; Austin PC; Anderson GM
J Clin Epidemiol; 2018 Sep; 101():79-86. PubMed ID: 29879465
[TBL] [Abstract][Full Text] [Related]
20. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
